

抗丙肝病毒药物靶标计量分析及趋势研究

立即下载

Quantitative analysis and developing trend research on anti- HCV drug targets

田军;郝博济;

摘要:

本文借助Thomson Reuters Pharma信息平台,以不同靶标药物在各研发阶段的数量分布为主要参考指标,辅以相关文献和典型药物资料,对抗丙肝病毒药物的研发现状进行了统计、分析和研究,并对其可能的发展趋势和方向做出了预测和判断。得出以下主要结论:(1)干扰素 α 是目前治疗丙型肝炎病毒(HCV)感染的主要药物,但在新药研发中的地位有所下降;(2)NS3蛋白酶和NS5B聚合酶是目前抗HCV新药开发研究最热的靶标,已上市的两种NS3蛋白酶抑制剂均取得了巨大成功,但数据也反映出这两类药物相对较高的研发难度;(3)NS5A蛋白靶标是抗HCV新药开发的新兴方向,未有药物上市,但临床研究取得了良好的预期效果,并得到专业分析机构的青睐。

关键词: 肝炎病毒;;干扰素类;;抗病毒药;;NS3蛋白酶;;NS5B聚合酶

基金项目:天津市科技支撑计划重大项目(11ZXPTJH00200)和(11SYSYJH00100)

通讯作者: 田军;

Email:

参考文献:

- [1]MCGIVERN DR,LEMON SM.Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer[J].Oncogene,2011,30(17):1969-1983.
- [2]ALY HUSSEIN H,SHIMOTOHNO K,HIJIKATA M,et al.Invivo models for analysis of the hepatitis C virus life cycle[J].Microbiol Immunol,2012,56(1):1-9.
- [3]HELBIG KJ,BEARD MR.The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment[J].Biomark Med,2012,6(2):141-150.
- [4]BOLEWSKA B,CZAJKA A,MOCZKO J,et al.Interferon alpha, gamma, omega before and during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin [J].Przegl Epidemiol,2007,61(4):755-763.
- [5]KAPPOS L,HARTUNG HP.10 years of interferon beta-1b(Betaferon)therapy[J].J Neurol,2005,252 Suppl 3:iii1-iii2.
- [6]MORAN MS.Method for treating hepatitis C virus with omega interferon:US,07727519[P].2010-01-01.
- [7]SCHULTZ B,YANG H,DELANEY WE 4th.Biochemical evaluation of HCV NS3 protease inhibitors

扩展功能

● 本文信息

[PDF\(221K\)](#)[参考文献](#)

● 服务与反馈

[引用本文](#)

● 本文关键词相关文章

[肝炎病毒](#)[干扰素类](#)[抗病毒药](#)[NS3蛋白酶](#)[NS5B聚合酶](#)

● 本文作者相关文章

[田军](#)[郝博济](#)

● 中国知网

[田军](#)[郝博济](#)

- [J]. *Curr Protoc Pharmacol*, 2011, Chapter 13 Unit: 13B.7.
- [8] TSANTRIZOS YS. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection [J]. *Curr Opin Investig Drugs*, 2009, 10(8):871-881.
- [9] WATKINS WJ, RAY AS, CHONG LS. HCV NS5B polymerase inhibitors [J]. *Curr Opin Drug Discovery Dev*, 2010, 13(4):441-465.
- [10] POWDRILL MH, BERNATCHEZ JA, GOTTE M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B [J]. *Viruses-Basel*, 2010, 2(10):2169-2195.
- [11] SOFIA MJ, CHANG WS, FURMAN PA, et al. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase [J]. *J Med Chem*, 2012, 55(6):2481-2531.
- [12] BRILLANTI S, MAZZELLA G, RODA E. Ribavirin for chronic hepatitis C: and the mystery goes on [J]. *Dig Liver Dis*, 2011, 43(6):425-430.
- [13] TSUBOTA A, FUJISE K, NAMIKI Y, et al. Peginterferon and ribavirin treatment for hepatitis C virus infection [J]. *World J Gastroenterol*, 2011, 17(4):419-432.
- [14] LALEZARI J, LAWITZ E, RODRIGUEZ-TORRES M, et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2B trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3 [J]. *J Hepatol*, 2011, 54:S28.
- [15] GUEDJ J, DAHARI H, SHUDO E, et al. Hepatitis C virus kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128) [J]. *Hepatology*, 2012, 55(4):1030-1037.
- [16] PATEL R, THOMPSON P, SHOWALTER R, et al. In vitro combination studies of ANA598 with anti-HCV agents demonstrate enhanced anti-viral activity [J]. *Antiviral Res*, 2010, 86(1):A41-A42.
- [17] MORIYAMA M, KATO N, OTSUKA M, et al. Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A [J]. *Hepatology International*, 2007, 1(2):302-310.
- [18] RODRIGUEZ A, OLIVA C, GONZALEZ M. A comparative QM/MM study of the reaction mechanism of the hepatitis C virus NS3/NS4A protease with the three main natural substrates NS5A/5B, NS4B/5A and NS4A/4B [J]. *Phys Chem Chem Phys*, 2010, 12(28):8001-8015.
- [19] SILLANPAA M, MELEN K, PORKKA P, et al. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection [J]. *Virol J*, 2009, 6:84.
- [20] WANG C, HUANG H, VALERA L, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 [J]. *Antimicrob Agents Chemother*, 2012, 56(3):1350-1358.
- [21] REVIRIEGO C. Daclatasvir dihydrochloride treatment of hepatitis C virus HCV NS5A inhibitor [J]. *Drugs Future*, 2011, 36(10):735-739.
- [22] MARTINEZ MIR I, ESTAN L, RUBIO E, et al. Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole [J]. *J Pharm Pharmacol*, 1988, 40(9):655-656.
- [23] EINAV S, SOBOL HD, GEHRIG E, et al. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors [J]. *J Infect Dis*, 2010, 202(1):65-74.
- [24] ANGUS AG, PATER AH. Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2 [J]. *Future Microbiology*, 2011, 6(3):279-294.
- [25] GORDON FD, CHUNG RT, CURRY MP, et al. Monoclonal antibody MBL-HCV1 suppresses return of HCV following liver transplantation [J]. *Hepatology*, 2011, 54 Suppl:1434A.
- [26] BELON CA, FRICK DN. Hepatitis C virus NS3 helicase inhibitors, in hepatitis C: antiviral drug discovery and development [M]. Caister Academic Press, 2011:237-256.
- [27] FRICK DN. The hepatitis C virus NS3 protein: A model RNA helicase and potential drug target [J]. *Current Issues Mol Biol*, 2007, 9(1):1-20.
-